Actinium Pharmaceuticals Q2 2024 GAAP EPS $(0.38) Beats $(0.43) Estimate
Portfolio Pulse from Benzinga Newsdesk
Actinium Pharmaceuticals (AMEX:ATNM) reported a Q2 2024 GAAP EPS of $(0.38), beating the analyst consensus estimate of $(0.43) by 11.63%.
August 06, 2024 | 3:44 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Actinium Pharmaceuticals reported a Q2 2024 GAAP EPS of $(0.38), which is better than the analyst consensus estimate of $(0.43). This positive earnings surprise may boost investor confidence in the short term.
The company's reported EPS was better than expected, which is likely to be viewed positively by investors. This could lead to a short-term increase in the stock price as it indicates better-than-expected financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100